Pacylex Pharmaceutical Explores N-myristoyltransferase Inhibitors as Potential ADC Cancer Therapies
Pacylex Pharmaceuticals is presenting innovative research on N-myristoyltransferase (NMT) inhibitors as potential payloads for antibody drug conjugates (ADCs), highlighting promising early clinical results in cancer treatment across multiple tumor types.
Pacylex Pharmaceuticals is advancing a novel approach to cancer treatment by exploring N-myristoyltransferase (NMT) inhibitors as potential payloads for antibody drug conjugates (ADCs). At the 2nd Annual ADC Payload Summit, CEO Michael Weickert will present research demonstrating the potential of these inhibitors to target multiple cancer cell processes.
The company's lead compound, zelenirstat, has shown promising early clinical results across different cancer types. In a Phase 1 study involving 24 heavily pretreated patients with non-Hodgkin's lymphoma and solid tumors, 57% of patients experienced stable disease or better for 6-16 months. One patient with diffuse large B-cell lymphoma achieved a partial response.
Pacylex's research indicates that NMT inhibitors can simultaneously disrupt critical cancer cell mechanisms. These inhibitors block myristoylation required for protein assembly and function, interfere with cellular receptor complexes, and inhibit mitochondrial energy production essential for metastasis and cancer stem cell survival.
The company possesses an extensive portfolio of 503 NMT inhibitors, with 28 demonstrating potent activity against human NMT1. This diverse collection positions Pacylex to explore potential ADC payloads across multiple cancer types, potentially offering a more targeted and effective treatment approach.
Zelenirstat has already received significant regulatory recognition, including Orphan Drug Designation and Fast Track Designation from the FDA for acute myeloid leukemia treatment. The US Department of Defense is supporting initial clinical investigations, underscoring the compound's potential clinical significance.
As the pharmaceutical industry continues seeking more precise cancer therapies, Pacylex's research into NMT inhibitors represents a promising avenue for developing more effective, targeted treatment strategies that could potentially improve patient outcomes across various cancer types.